Research Topics
Detailed analysis of therapeutic indications, mental health conditions, and scientific themes in the evolving landscape of psychedelic research.
Looking for something specific? Ask Blossom
Topic overview
Adolescents
Adolescents are a developing-brain, vulnerable population that the modern psychedelic field has mostly studied from the outside: almost all psychedelic trials enrol adults, not minors. The one mature clinical thread in under-18s is ketamine and esketamine for depression and acute suicidality, where benefits are real but modest and often matched by active-placebo arms. For classic psychedelics like psilocybin, LSD and MDMA there is essentially no controlled evidence in adolescents, and the developing brain raises safety questions that adult data cannot answer.
Topic overview
Alcohol Use Disorder (AUD)
Alcohol use disorder is where psychedelics have their strongest single result in addiction: a 2022 double-blind trial found that psilocybin plus psychotherapy roughly halved heavy drinking compared with an active placebo. It is a genuine landmark, but it is still one positive Phase 2 trial, and two further double-blind psilocybin trials in 2025 were less encouraging, one finding no benefit. Ketamine has a real abstinence signal, and LSD has famous but dated 1960s evidence. The promise here is real and the best in the addiction field, but not yet settled.
Topic overview
Anxiety Disorders
Anxiety disorders are the most common mental health conditions in the world, yet for primary anxiety (generalised anxiety, social anxiety, panic) the psychedelic evidence is surprisingly thin. The clear front-runner is LSD: MindMed’s MM120 met its Phase 2b endpoint in generalised anxiety disorder and is now in two Phase 3 trials. Most other psychedelic anxiety data comes from cancer and end-of-life distress, a different problem covered on our palliative page, or is measured as a side effect of treating depression.
Topic overview
Autism Spectrum Disorder (ASD)
Autism is a lifelong neurodevelopmental difference, not a disease, and the serious, neurodiversity-affirming research here is not about treating or curing autism. It is about whether psychedelics can help with conditions that autistic people experience at high rates and may want help with, above all social anxiety. The evidence is a single, much-cited pilot: a small randomised trial in which MDMA-assisted therapy reduced social anxiety in autistic adults, with benefits lasting six months. That signal is genuine but tiny, the field has a troubling history of experiments done to autistic children rather than with autistic adults, and there are real safety and consent considerations. This is early research, not an available treatment.
Topic overview
Bipolar Disorder
Bipolar disorder is the area where the honest message about psychedelics is caution, not promise. Classic psychedelics such as psilocybin and LSD can trigger mania or hypomania, so people with bipolar disorder are excluded from almost every psychedelic trial, and combining them with lithium can cause seizures. The compound with real bipolar evidence is ketamine, used as a closely monitored, short-acting add-on to a mood stabiliser. One small, intensively supervised psilocybin trial in bipolar II is an early, fragile exception, not a green light.
Topic overview
Borderline Personality Disorder (BPD)
Borderline personality disorder is an unusual case in psychedelic research, because the people it affects have mostly been kept out of it. BPD involves intense emotional swings, unstable relationships and self-image, impulsivity and high rates of self-harm, and those same features, especially suicidality and a tendency to dissociate, have made BPD a standard reason to be excluded from psychedelic trials. So the direct evidence is almost non-existent, and what little exists is not encouraging: the one randomised trial, of ketamine, was negative. The rationale is real, BPD overlaps heavily with trauma and is fundamentally about emotion regulation, which is what these therapies aim at, but it sits against a genuine risk of destabilisation and a proven psychotherapy that works. This is a hypothesis, handled with care, not a treatment.
Topic overview
Chronic Pain
Chronic pain is one of the few areas here where the compound with real evidence is not a classic psychedelic but ketamine, a dissociative anaesthetic with a genuine, if short-lived, analgesic effect. The psilocybin and LSD story for chronic pain is much earlier: small open-label pilots, case reports and healthy-volunteer experiments, with no controlled trials yet. Much of the apparent benefit may come from easing the depression and distress that travel with chronic pain rather than from blocking pain itself.
Topic overview
Creativity
Few beliefs about psychedelics are more widely held than that they unlock creativity, and few are less supported by controlled evidence. The cultural prior is enormous, artists, inventors and technologists have long credited these drugs with creative breakthroughs, but when researchers measure creativity properly, double-blind and against a placebo, the effect mostly evaporates. The most reliable finding in the whole literature is a dissociation: people feel markedly more creative while their measured performance is unchanged or, on some tasks, worse. Acute doses tend to raise novelty while lowering usefulness and impairing the kind of focused thinking that turns a wild idea into a finished one. Microdosing fares no better, beating placebo on essentially nothing. This page is about that gap between a powerful, sincere experience of creativity and the stubborn difficulty of showing it on a test.
Topic overview
Depressive Disorders
Depression is the flagship indication for psychedelic and rapid-acting psychiatry, and the place where the field has gone furthest: an approved drug (esketamine), the first Phase 3 win for a classic psychedelic, and several striking trials of psilocybin for major depression. But it is also where the honest caveats bite hardest. The most rigorous recent analyses suggest much of psilocybin’s apparent edge comes from patients knowing they got the drug, and a head-to-head against a standard antidepressant was not significant on its main measure. This is the umbrella page for the depression family; the resistant, general and bipolar forms each have their own.
Topic overview
Eating Disorders
Eating disorders, especially anorexia nervosa, are among the most serious conditions in psychiatry: anorexia has one of the highest mortality rates of any mental illness, and effective treatments for adults are genuinely scarce. That unmet need is why psychedelic research here is taken seriously. But this is also one of the field’s most preliminary and most safety-sensitive areas. The flagship study was a small feasibility trial that showed psilocybin could be given safely to medically fragile patients, not that it works; the efficacy signals are early and mixed, the MDMA evidence is indirect, and one major trial was withdrawn. This is supervised research in a high-risk group, not an available treatment, and nothing here should be attempted outside a trial.
Topic overview
Equity and Ethics
The science of psychedelics arrives wrapped in hard ethical questions, and this page is about them: who gets included in the research, who is left out, who profits, and who bears the risks. Some of this is genuinely measured. Clinical trials have been strikingly un-diverse, the protective population findings hold mainly for White people, documented abuses scar the field’s history, and the people with the greatest need are often those with the least access. Much of the rest is argument rather than evidence: about reciprocity with the Indigenous communities whose medicines this industry is built on, about the impossibility of clean consent in an altered state, about patenting traditional knowledge, and about safeguarding people at their most vulnerable. The honest task here is to keep the documented facts and the ethical reasoning distinct, and to take both seriously, because a treatment that works but reaches only the privileged, or harms the trusting, is not a success.
Topic overview
Fibromyalgia
Fibromyalgia is, in one important sense, the pain condition that should fit psychedelics best. Its pain is not coming from damaged tissue but from a nervous system that amplifies pain signals, a problem of central processing wrapped in fatigue, poor sleep, brain fog and frequent depression. That is exactly the kind of brain-level, affectively-loaded problem the idea of "resetting" pain processing is meant for, which is why there is real research interest. But the evidence is still at the starting line. The headline human study tested psilocybin in just five people, without a control group; ketamine eases the pain briefly but a controlled trial found the benefit did not last; and most of the enthusiasm comes from patient surveys. A genuinely promising rationale, in other words, with barely any proof behind it yet.
Topic overview
Headache Disorders (Cluster & Migraine)
Headache disorders are where the psychedelic story took its most unusual route: it started with patients. People with cluster headache, among the most severe pain known to medicine, found that low doses of psilocybin or LSD could abort or hold off their attacks, and organised to study it long before the labs caught up. The science that followed is genuinely distinctive, the benefit seems to work at low doses without needing a psychedelic experience and may act on the brain’s headache circuitry rather than on mood. But it is also genuinely unproven: the small controlled trials in both cluster headache and migraine did not beat placebo on their main measures. This is a promising, patient-driven, mechanistically interesting lead that still lacks a convincing trial.
Topic overview
Health Economics & Reimbursement
Will psychedelic therapy save money or break budgets? The economic studies are strikingly upbeat, with headline claims that MDMA therapy for trauma is "cost-saving" and that scaling it could save billions. But almost every one of those numbers is the output of a model, a spreadsheet built on assumptions about how well the therapy works, how long the benefit lasts, how cheaply it can be delivered, and what it will cost, rather than a measured economic result. Change the assumptions and the conclusions move dramatically: the same drug can look cost-saving over thirty years and merely acceptable over one, cost-effective to society but unaffordable to a health system. The molecule is cheap; the hours of skilled therapy around it are not, and that is what really drives the sums. Only ketamine has real-world cost data and actual insurance coverage; for the classic psychedelics, the economics, like the reimbursement, are still almost entirely on paper.
Topic overview
Healthy Volunteers
Healthy-volunteer research is not about treating anyone, and that is the point. These are the controlled studies in people without a mental illness that establish the basic facts of the field: what psychedelics do, at what doses, for how long, how safe they are, and how they change the brain, without the confounds that illness brings. They are the most rigorous part of psychedelic science and, at the same time, the source of its most seductive findings, the mystical experiences and personality shifts that fuel the hype. They also reveal the field’s hardest methodological problems, from the near-impossibility of blinding to the gap between a curious volunteer and a suffering patient. Read well, this is where the evidence is firmest; read carelessly, it is where over-claiming begins.
Topic overview
Immunology & Inflammation
One of the more surprising ideas in psychedelic science is that these drugs might be powerful anti-inflammatories, acting on the same serotonin 2A receptor that produces their psychological effects, and that some of their benefit for depression might come from calming inflammation rather than from the experience at all. It is a genuinely interesting hypothesis, and it is also one of the field’s most preclinical. The striking effects come almost entirely from mouse, rat and cell studies, and the molecule that carries the headline mechanism is a research chemical, not a medicine. In humans the picture is thin and mixed: small, short-lived cytokine changes that sometimes appear and sometimes do not, one study finding the classic psychedelics do nothing to immune cells directly, and no completed trial in any actual inflammatory disease. This page lays out the exciting mechanism and the sober reality of how little of it has been shown in people.
Topic overview
Implementation & Service Delivery
A psychedelic therapy that works in a trial still has to be delivered in the real world, to many people, affordably, safely and well, and that turns out to be one of the hardest unsolved problems in the field. This page is about the mechanics: who delivers the therapy, how they are trained, whether sessions are one-to-one or in groups, how it fits into a health system, and what it costs. The honest picture is of a field still improvising. Real-world data are thin, dominated by ketamine clinics and a handful of feasibility pilots; the psychological-support component is essential but contested and hard to standardise; the trained workforce needed is enormous and does not yet exist; and the most-discussed solution, group delivery, promises big savings on paper while remaining unproven in practice. The science of whether these therapies work is racing ahead of the much harder question of how to actually provide them.
Topic overview
Interpersonal Functioning & Social Connectedness
Few claims about psychedelics are as appealing as the social one: that they make people feel more connected, more empathic, more at ease with others. This page examines what the evidence actually supports. The firmest finding is that MDMA acutely increases empathy, trust and warmth, an effect specific enough to separate it from a plain stimulant and linked to the hormone oxytocin. Classic psychedelics raise emotional empathy too, though not social understanding. But "connectedness" has also become a catch-all, a single fuzzy idea stretched to explain everything these drugs do, and the evidence for durable change in real relationships is thin. Most of it is acute, self-reported, and gathered in healthy volunteers. This is a real and interesting domain of effect, and one where the warm language runs well ahead of the hard outcomes.
Topic overview
Major Depressive Disorder (MDD)
Major depressive disorder is the most common form of depression and, somewhat unexpectedly, the place where psilocybin has its strongest randomised evidence: the landmark trials enrolled people with major depression who were not treatment-resistant. Yet no psychedelic is approved for general major depression, and esketamine, the one approved rapid-acting drug, is licensed only for the resistant form and for depression with acute suicidality. The honest reading is genuine promise set against modest, hard-to-blind effects and a head-to-head with a standard antidepressant that ended in a draw. This page covers general, first-line major depression; the resistant subset and the family overview have their own pages.
Topic overview
Medicinal Chemistry & Drug Development
Medicinal chemistry is the engineering side of psychedelic research: the work of designing, tuning and manufacturing the molecules themselves, and turning them into drug candidates. It is where the field tries to keep what is useful about these compounds while removing what is risky or inconvenient, by editing chemical structures to change potency, duration and receptor selectivity, by reformulating known drugs, and, most ambitiously, by trying to build "non-hallucinogenic" versions that might keep a therapeutic effect without the trip. Most of this is early, preclinical chemistry, and one of its central premises, that the experience can be removed without losing the benefit, is a genuine and unresolved scientific dispute. This page covers what the chemistry has actually achieved, what is still a hypothesis, and where the science ends and the patent strategy begins.
Topic overview
Microdosing
Microdosing, taking tiny, sub-perceptual doses of a psychedelic a few times a week for focus, mood or creativity, is one of the most popular things people do with these drugs, and one of the clearest cases where rigorous evidence undercuts a popular practice. The anecdotes are glowing, the surveys are positive, and the open-label studies look promising. But when researchers run proper double-blind, placebo-controlled trials, the benefits very largely disappear: people on placebo improve just as much, and the small differences that remain track whether participants guessed they had the real drug. This page tells that story honestly. It also notes the two things the null trials do not settle: whether some narrow effect survives in the right population, and whether taking a serotonergic drug repeatedly for months or years is safe, which, remarkably, almost nobody has properly studied.
Topic overview
Neurocognitive Disorders
Neurocognitive disorders, including dementia, Alzheimer's disease, Parkinson's disease and traumatic brain injury, involve a progressive decline in memory, thinking and everyday function. Interest in psychedelics here rests on a strong biological rationale and early human safety signals, not on proven treatment: no completed controlled trial yet shows that psychedelics treat dementia or restore lost cognition.
Topic overview
Neuroimaging & Brain Measures
Neuroimaging is a measurement lens, not a treatment. Brain scans (fMRI, EEG and MEG, PET) are how researchers watch what psychedelics actually do to the living human brain: the acute loosening of its normal network architecture, the surge in signal complexity, the receptor occupancy that tracks how intense an experience feels, and the slower changes that may follow a dose. This is some of the most fascinating science in the field, and some of the most easily over-read. The images are vivid and the samples are usually tiny, and a striking brain change is not a clinical outcome. This page covers what imaging has genuinely established, what is still exploratory, and why a picture of a brain on psychedelics tells you what the drug does, not that it works as a medicine.
Topic overview
Neurological Injury
Neurological injury, the broad family that includes stroke, traumatic brain injury, oxygen-deprivation injury and spinal cord injury, is the least-developed area of psychedelic research on this site, and the one where the gap between hope and evidence is widest. As with brain injury generally, almost none of the work is about repairing damaged tissue; it is about the depression, anxiety, post-traumatic stress and lost functioning that follow, and, in animals, about whether psychedelics can nudge the brain’s own recovery. The single human result with real weight sits in the traumatic brain injury sub-topic (an uncontrolled magnesium-ibogaine study in veterans). Everywhere else the evidence is preclinical or very early, and ketamine’s main role is in acute intensive care, not psychedelic therapy.
Topic overview
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive disorder is one of the oldest ideas in psychedelic psychiatry: the first prospective study of psilocybin for OCD appeared in 2006, years before the depression trials that made the field famous. Yet it remains one of the least-proven. Small studies reliably show that a psychedelic can cut OCD symptoms acutely, and a 2026 trial became the first to beat a placebo, but the sample was tiny and the most striking numbers came from an open-label extension. The honest picture is a genuinely intriguing, mechanistically distinctive signal that, after two decades, is still essentially proof-of-concept, with no approved psychedelic treatment and SSRIs plus therapy remaining the standard of care.
Topic overview
Older Adults
Older adults are the group with the most late-life depression, the most to gain from a new option, and the least evidence to go on. They have been almost entirely left out of psychedelic trials: a 2024 review found fewer than 1.4% of participants were 65 or older. So nearly everything said about psychedelics for older people is extrapolated from younger, healthier volunteers, even though this is the group most exposed to the real risks, from drug interactions with everyday medications to the strain a temporary rise in blood pressure puts on an older heart. The one compound with genuine older-adult data is ketamine, for late-life depression, and even its dedicated elderly trial fell short. This page is about that gap as much as any promise.
Topic overview
Opioid Use Disorder (OUD)
Opioid use disorder is one of the deadliest addictions, and it is also the one where the honest message about psychedelics needs the most care. Effective, life-saving medicines already exist, methadone and buprenorphine more than halve the risk of death, and nothing here should be read as a reason to stop them. Against that backdrop, ibogaine can sharply reduce opioid withdrawal and craving in a single dose, but it can also cause fatal heart rhythm problems and has been linked to dozens of deaths. Ketamine has older positive trials and psilocybin is only just entering testing. The interest is real; the proof, and the safety, are not yet there.
Topic overview
PTSD
Post-traumatic stress disorder (PTSD) is where psychedelic medicine has its most famous result and its hardest reality check. MDMA-assisted therapy ran the only completed Phase 3 programme for any psychedelic in PTSD, with striking numbers, yet in August 2024 the US regulator declined to approve it and asked for another trial. This page sets the strongest evidence in the field beside the unresolved doubts about blinding, durability and trial conduct that the regulator flagged.
Topic overview
Palliative & End-of-Life Distress
Distress at the end of life, the fear, depression and loss of meaning that can accompany a terminal diagnosis, is the oldest indication in modern psychedelic research and the source of some of its most famous results. Two landmark 2016 trials found that a single dose of psilocybin produced rapid, large and lasting reductions in anxiety and depression in people with life-threatening cancer. The findings are striking, but the evidence base is small, the trials are hard to blind, and no psychedelic is approved anywhere for this use.
Topic overview
Peripartum
The peripartum period is an unusual corner of this field, because here the race for a fast-acting treatment has already been won, and not by psychedelics. Postpartum depression now has approved rapid-acting drugs, brexanolone and the oral pill zuranolone, but these are neurosteroids, a different class entirely. Classic psychedelics, meanwhile, are largely shut out of pregnancy and breastfeeding on safety grounds: the risks to a fetus or nursing infant are unknown, and a parent cannot be incapacitated for hours while caring for a newborn. The real psychedelic-adjacent activity is perioperative ketamine to prevent postpartum depression, where the evidence is genuine but mixed, and a newer effort to design ultra-short-acting psychedelics specifically for this window. It is early, complicated by real safety limits, and the most eye-catching result so far was uncontrolled.
Topic overview
Personality & Trait Factors
One of the most repeated claims about psychedelics is that they change who you are: that a single experience can durably raise "openness" and reshape personality. It is a powerful story, and it is shakier than its reputation. The honest version is more modest and more interesting. The trait that most reliably shifts in controlled trials is not openness but neuroticism, which falls, and that overlaps heavily with simply feeling better. Openness changes are often small, sometimes no greater than under a standard antidepressant, and rarely shown to last. The largest "openness" figures come from comparing people who already chose to take psychedelics with people who did not. This page separates the genuine signal (modest, mostly in patients, easy to confuse with symptom relief) from the myth, and notes that personality may matter more as a predictor of the experience than as something the drug rewrites.
Topic overview
Personality Disorders
Personality disorders are defined by rigid, long-standing patterns of thinking, feeling and relating, which makes them a tantalising and difficult target for psychedelics. The tantalising part is the theory: these drugs loosen mental rigidity and have been shown to shift personality traits, at least in other populations, so the idea of softening an entrenched pattern is genuinely appealing. The difficult part is the evidence, which is almost entirely absent. What little exists is concentrated in borderline personality disorder, which has its own page and where the direct findings are not encouraging, plus a scatter of early work in conditions like pathological narcissism. And part of this family, the disorders on the schizophrenia spectrum, carries the same psychosis caution that makes psychedelics a contraindication, not a treatment. The honest status is an interesting idea with very little behind it.
Topic overview
Premenstrual Dysphoric Disorder (PMDD)
Premenstrual Dysphoric Disorder (PMDD) affects 5.5% of menstruating women with severe cyclical mood symptoms. This page includes an original exploratory research report investigating how women with PMDD use psilocybin, alongside evidence matrices and treatment landscape analysis.
Topic overview
Public Health, Prevention & Behaviour Change
Most psychedelic research looks at one patient at a time. This page zooms out to the population: what large surveys, naturalistic cohorts and policy models suggest about psychedelics and public health, and how far that is from proof. The picture is genuinely interesting and genuinely limited. Big epidemiological datasets find that people who have used psychedelics are no worse off on mental health, and sometimes show lower rates of problem substance use, but these are correlations in self-selected people, not effects of the drug. The leap from a promising clinical trial to a real public-health impact is largely unmade: when trial entry criteria are applied to the wider patient population, most people would not even be eligible. This is a topic where the vision is bold, the modelling is optimistic, and the hard population evidence is thin and correlational.
Topic overview
Safety & Risk Management
Safety is the most important subject in this field, and the most easily misrepresented. Under careful screening and supervision, psychedelics have a reassuring acute safety profile: serious harm in modern trials is rare, and the common effects (nausea, anxiety, a transient rise in blood pressure and heart rate) are manageable. But that reassurance is a property of the trial, not just the drug: it comes from excluding the people most at risk and watching everyone closely. The real-world picture is harder, dominated by drug interactions, vulnerable individuals, and unsupervised settings. This page is an honest account of the genuine risks, how serious and how common each is, who is most exposed, and how the field tries to manage them, without the reflexive "remarkably safe" that the evidence does not support.
Topic overview
Schizophrenia
Schizophrenia is the exception to almost everything else in psychedelic medicine. Here, classic psychedelics are not a candidate treatment but a contraindication: a personal or family history of psychosis is one of the most consistent reasons people are excluded from psychedelic trials, because drugs like psilocybin and LSD can trigger or worsen psychotic symptoms. The reason schizophrenia appears so often in this research is the opposite of treatment, it has long served as a model of psychosis, first through LSD and mescaline, later and more powerfully through ketamine. There are only narrow, cautious research threads around comorbid symptoms, and a separate effort to design non-hallucinogenic drugs inspired by this biology. The honest headline is a warning, not a therapy.
Topic overview
Set & Setting
"Set and setting" is the field’s oldest and most repeated idea: that what a psychedelic does depends as much on the person’s mindset (set) and the physical and social environment (setting) as on the drug itself. It is genuinely important, and it is also the most over-used phrase in psychedelic science. The honest picture is mixed. There is real evidence that context matters, that the people in the room, the music and a person’s expectations shape the experience, but it is mostly observational, and the field is only now agreeing on how to measure "setting" at all. At the same time, the idea is easy to abuse: it can explain away any inconvenient result, and it overlaps awkwardly with the expectancy and unblinding problems that inflate how well these drugs appear to work. This page separates what is established from what is merely asserted.
Topic overview
Substance Use Disorders (SUD)
Addiction is one of the oldest hopes for psychedelic medicine, going back to LSD trials for alcoholism in the 1950s. Today psilocybin is the workhorse, with positive trials in alcohol, tobacco and cocaine use disorders, and the cross-substance signal is real. But the picture is mixed rather than settled: a major alcohol trial was null, the studies are small, and almost all of them struggle to keep patients unaware of whether they got the drug. This page is the hub; alcohol, opioid and tobacco use disorders have their own dedicated pages.
Topic overview
Suicidality
Suicidality covers the spectrum of suicidal thoughts, plans and behaviours, and it contributes to more than 727,000 deaths worldwide each year. The strongest evidence for rapidly reducing suicidal thinking is for ketamine and esketamine, and esketamine carries a specific regulatory approval. But even there, a reduction in suicide itself has not been proven, and classic psychedelics remain unproven for suicidality and can carry real risks for people in crisis. This is a research summary, not medical advice.
Topic overview
Tobacco/Nicotine Use Disorder (TUD)
Tobacco use is one of the world’s biggest causes of preventable death, and quitting is famously hard. The most striking psychedelic result here is from psilocybin: a small Johns Hopkins pilot reported that most heavy smokers were still abstinent six months after a couple of supervised doses paired with quit-smoking therapy. In 2026 a controlled trial finally tested it head to head against the nicotine patch and psilocybin won, though the real-world abstinence figure was far lower than the famous pilot, and the trial could not be properly blinded. The signal is real and encouraging, but the evidence is still small and early.
Topic overview
Traumatic Brain Injury (TBI)
Traumatic brain injury is one of the more misunderstood corners of psychedelic research, because almost none of it is actually about repairing the brain. The work that matters here targets the psychiatric and functional after-effects of TBI, the depression, anxiety, post-traumatic stress and disrupted functioning that often follow, especially in veterans exposed to blasts. The standout result is a striking but uncontrolled study of magnesium-ibogaine in 30 special-operations veterans, who reported large improvements in those symptoms. It is genuinely interesting and genuinely preliminary: observational, self-selected, conducted abroad, and using a drug that can stop the heart. Beyond it, the evidence is mostly animal studies and early observations, and ketamine’s main role in TBI is a separate, intensive-care one.
Topic overview
Treatment-Resistant Depression (TRD)
Treatment-resistant depression, depression that has not responded to at least two adequate antidepressant trials, is where psychedelic and rapid-acting therapies are furthest along. Esketamine is FDA-approved, and in 2025 a synthetic psilocybin became the first classic psychedelic to meet a Phase 3 endpoint for depression. The progress is real, but so are the caveats: modest effect sizes, short-lived benefits, and unresolved questions about how well these trials are blinded.
Topic overview
Veterans
Veterans carry an unusually heavy burden of PTSD, depression, traumatic brain injury, moral injury and suicidality, and many do not respond to standard treatment. That unmet need has put them at the centre of psychedelic research, and of an intense real-world demand. The evidence is genuinely promising but still early and mostly uncontrolled, and in 2024 the US FDA declined to approve MDMA-assisted therapy for PTSD.